Rethinking JAK2 Inhibition: Towards Novel Strategies of More Specific and Versatile Janus Kinase Inhibition
(2017) Leukemia — Vol. 31, n° 5, p. 1023-1038 (2017)
Files
Details
- Authors
- Abstract
- Janus kinases (JAKs) are required for cytokine receptor signaling. Since the discovery of the highly prevalent JAK2 V617F mutation in myeloproliferative neoplasms (MPNs), JAK2 became a prime target for inhibition. Only one approved JAK2 inhibitor exists, with positive, but not curative effects in MPNs, and promising effects in autoimmune diseases and cancer. Based on recent advances in the structural features regulating both normal and mutant JAKs, as well as in small-molecule targeting, we review the current state of JAK2 inhibitor development and present novel avenues of selecting JAK2 inhibitors, with broad and narrow specificities and extend these approaches to other JAKs.
- Affiliations
Citations
Leroy, E., & Constantinescu, S. (2017). Rethinking JAK2 Inhibition: Towards Novel Strategies of More Specific and Versatile Janus Kinase Inhibition. Leukemia, 31(5), 1023-1038. https://doi.org/10.1038/leu.2017.43 (Original work published 2017)